Qingfei Zhike Powder Veterinary Grade API is a multi-component botanical active pharmaceutical ingredient intended for formulation into tablets, injections, capsules, powders, granules, premixes, and solutions for veterinary use. The material is derived from the compendial formula Qingfei Zhike San and is not supplied as a finished dosage unit. “API grade” in this context indicates a controlled powder that has undergone milling, sieving, blending, and analytical release testing for marker content, moisture, ash, heavy metals, and microbial burden. No official model number is assigned by pharmacopoeial nomenclature; purchasing documentation should therefore identify the material by compendial name, manufacturer lot, and the applicable analytical profile. The powder is intended for further manufacturing, and when the target dosage form is an injectable solution, additional dissolution, pH adjustment, prefiltration, and sterile filtration or aseptic filling are mandatory. Published data for this specific configuration is limited, particularly for single-marker pharmacokinetic equivalence across species.

What compendial and customer specification parameters are applied to the veterinary-grade powder?

The release framework for oral solid and premix inputs follows the Chinese Veterinary Pharmacopoeia monograph for Qingfei Zhike San, supplemented with ISO methods for microbial enumeration and trace-element analysis. A specification sheet should define appearance, identification by thin-layer chromatography against reference materials for Scutellaria baicalensis, Platycodon grandiflorum, and Glycyrrhiza uralensis, marker assay by HPLC, loss on drying, total ash, acid-insoluble ash, heavy metals, pesticide residues, aflatoxin screening, and microbial limits. Acceptance criteria are supply-chain-specific; without the manufacturer’s certificate of analysis, no universal limit can be substituted for a registered product. A typical input for encapsulation may be controlled at ≤ 7.0% loss on drying, while internally dried material may be controlled at ≤ 5.0% to reduce caking. Aerobic plate count for oral powders and premixes is commonly aligned with ISO 4833-1 and set at ≤ 10⁴ CFU/g or tighter where the finished product is intended for neonatal animals. Material planned for injectable processing requires bacterial endotoxin control, commonly ≤ 0.5 EU/mg, before aseptic filtration.

The powder should be stored in sealed moisture-barrier bags with desiccant below 25 °C and 60% relative humidity. Bulk density can shift after transport, and a re-blending step is often required before sampling because fine particles can segregate vertically in the shipping container. Fibrous botanical particles also tend to bridge in hoppers and dosing screws; a bin activator or mechanical stirrer is used on production-scale lines to maintain consistent delivery to the mill or sifter. At storage temperatures above 30 °C, the moisture equilibrium in the package can change even if desiccant remains present, and pressed tablets made from stored powder may exhibit longer disintegration times. Stability data specific to this botanical matrix should be generated under VICH conditions rather than extrapolated from synthetic APIs because the flavonoids and saponins undergo different degradation kinetics.

Direct compression of this API at high loadings is limited by compressibility, flow, and the hygroscopicity of certain botanical fractions. In a rotary tablet press with forced feeding, bulk density variation should be maintained within ± 10% of target before compression; otherwise die fill variation increases across turret stations. Formulation screening usually begins with API fractions up to 50 wt%, microcrystalline cellulose, pregelatinized starch, and a lubricant system of 0.5–1.0% magnesium stearate. The blend is prepared in a V-blender at 25 rpm for 15–20 min; over-blending can shear botanical fibers, raise the fines fraction below 75 µm, and increase tablet capping tendency. For capsule filling, the API is often passed through a 40-mesh (425 µm) screen and admixed with 0.2–0.5% colloidal silicon dioxide. The glidant is not a substitute for adequate drying because moisture above 7.0% can promote clumping inside the dosing disk and reduce fill weight consistency.

Processing windows for dry blending and aqueous granulation

Dry blending alone is often insufficient for tableting when the API contains particles of differing true density. Wet granulation in a high-shear mixer is applied to produce denser granules and reduce segregation. The liquid-to-solid ratio is generally kept low because the saponin-containing fractions from Platycodon root can generate foam and over-wetting; an endpoint is judged by impeller power draw or torque rather than by fixed granulation time. The wet mass is passed through a cone mill to a target granule diameter of 0.8–1.5 mm, then dried in a fluid-bed dryer with inlet air not exceeding 45 °C to avoid darkening heat-sensitive flavonoid constituents. Dried granules are sieved, and the 60–40 mesh fraction is preferred for tablet compression. If residual moisture rises above 5.0%, the granules can stick to punches and cause picking, particularly when the formulation contains no soluble filler. In aqueous granulation, processing should be stopped before the impeller torque reaches the upper control limit because over-granulation may produce hard granules with prolonged disintegration and reduced marker dissolution in quality-control media. A tablet batch at production scale may require re-optimization of compression speed and precompression force when the granule size distribution deviates by more than 10% from the established pattern.

Injectable solution manufacturing from the botanical API follows a different risk profile from oral granulation. The powder contains polysaccharides, saponins, and residual plant colloids that can form aggregates, precipitate at pH shifts below 3.0 or above 8.5, and foul sterilizing-grade membranes. Prefiltration through 0.45 µm polyethersulfone or nylon, followed by 0.22 µm hydrophilic PES, is required for a solution intended for terminal sterile filtration. The API is dissolved in Water for Injection at ≤ 40 °C, with slow addition to avoid lumping; the solution is then cooled to 20–25 °C before pH adjustment. Sodium hydroxide or hydrochloric acid may be used, but the pH should not be cycled because repeated titration can alter saponin-associated turbidity. Nitrogen blanketing is considered when baicalin degradation is observed under forced oxidation conditions. Published data for this specific configuration is limited, so filter compatibility and extractables should be tested with the exact solution matrix rather than extrapolated from simpler synthetic solutions.

When the powder is incorporated into injectable solutions, sterile filtration and pH adjustment become critical

The critical parameter is not filter rating alone but the sequence and membrane chemistry. Polysaccharide-associated turbidity is only partially removed by a 0.45 µm prefilter if the solution is above 25 °C; cooling before prefiltering reduces protein-polysaccharide complex mobility. The subsequent 0.22 µm membrane is selected from hydrophilic PES or nylon, and membrane area is sized to maintain flux below 200 L/m²/h. At higher flux, adsorption of saponin micelles onto the membrane surface increases differential pressure and shortens filter life. The aseptic holding time after filtration should be validated in accordance with current good manufacturing practice for veterinary products; the API itself is not sterile and cannot be assumed free of endotoxin unless the incoming specification includes endotoxin testing. Terminal heat sterilization is not universally applicable because water-soluble flavonoid glycosides may hydrolyze or darken at temperatures above 121 °C for typical 15-min cycles. This limitation separates the botanical API from heat-stable synthetic injectables such as bromhexine hydrochloride.

Premix uniformity and segregation risk in compound feed

For premix and granulated feed applications, the API is first diluted in a carrier such as calcium carbonate, rice hulls, or dextrose to a 1–10% active premix. Ribbon mixers with a capacity utilization of 50–80% are used, but botanical API of low bulk density can stratify when mixed with mineral carriers. Sampling for uniformity should follow a 10-point sampling plan and the coefficient of variation should be below 10% for active marker content. If the premix is stored above 60% relative humidity, the powder can absorb moisture, causing bridging in bin flow. Anti-caking agents are limited to those compatible with feed regulations; silicon dioxide at 0.5–1.0% may be acceptable in some jurisdictions, but its use must be verified against maximum limits in the target species. In pelleted feed, the API is exposed to post-pelleting steam temperatures, and published data on marker recovery after steam conditioning above 85 °C is limited. Conditional steam pressure should be selected so that the conditioned meal temperature remains below 80 °C where heat-sensitive flavonoid constituents are critical.

The API is used in compounded veterinary medicinal products for multi-species respiratory presentations characterized by coughing, tracheal rales, and nasal discharge within traditional Chinese veterinary indications of pulmonary heat. The degree of clinical response in controlled challenge studies is not consistently published; efficacy claims must be supported by the finished-product registration file in the target jurisdiction. Withdrawal periods for food-producing animals are not determined by the API alone, because residual marker depletion depends on the dosage form, extraction ratio, and co-formulated ingredients. A premix or oral solution containing the API may require a species-specific withholding period established by the finished-product applicant; the API supplier may not be able to supply regulatory maximum residue limit data unless the product is registered in the same jurisdiction.

Comparing release controls with synthetic mucolytics and crude powders

Qingfei Zhike Powder Veterinary Grade API differs from synthetic expectorants such as bromhexine hydrochloride in being a multi-component botanical material rather than a single chemical entity. The active fraction is not defined by one molecule; it consists of flavonoids, saponins, and polysaccharides whose relative proportions vary with botanical source and season. This variation creates a broader analytical burden than a synthetic API assay, because identification, marker assay, ash, heavy metals, pesticide residues, and microbial enumeration are all required. In contrast, a synthetic API can often be released by assay, related substances, residual solvents, water, and sulfated ash. The regulatory file for the botanical material is therefore less compact, and direct bioequivalence data are limited. Compared with unstandardized herbal powder, the veterinary-grade API is differentiated by controlled particle size, uniform blending, specified moisture, and microbial testing. The coarse farm-grade material may appear similar by simple color but often lacks defined particle-size distribution and can introduce batch-to-batch assay variation beyond ± 30%. The following matrix captures the primary release and processing distinctions.

For injectable batch manufacture, the most practical limitation is often prefilter capacity rather than the sterilizing-grade membrane. The 0.45 µm prefilter is sized by filterability testing on the actual bulk solution, because botanical solutions can show a rapid pressure rise if saponin aggregates exceed the estimated particle load. Inactive formulation components such as sodium chloride or phosphate buffers must be chosen after measuring the effect on zeta potential and turbidity; replacing a buffer system between development and scale-up can shift the particle-size distribution of suspended colloids and alter the flux profile. Equipment contact surfaces should be passive and free of exposed iron, because polyphenol-containing fractions can chelate metal ions and produce discoloration that does not necessarily indicate microbial contamination but can complicate visual inspection. The final filled solution should be evaluated for subvisible particulate matter by compendial light obscuration, not only by visual inspection, because botanical-derived particulates can appear below the threshold of manual detection and exceed injection limits if prefiltration is undersized.